EDIT – editas medicine, inc. (US:NASDAQ)
Stock Stats
News
6/26
10:12 am
edit
Low
seqWell Launches Loaded-transposase Portfolio to Support Expanding Use of NGS-based Gene Editing Analysis Methods [Yahoo! Finance]
6/18
01:12 pm
edit
Low
Editas Medicine, Inc. (NASDAQ: EDIT) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock.
6/14
03:12 am
edit
High
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress [Yahoo! Finance]
6/14
03:12 am
edit
High
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress [Yahoo! Finance]
6/14
03:01 am
edit
High
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
5/8/2024
07:00 am
edit
-10.1%
MISS
2/28/2024
07:00 am
edit
24.5%
BEAT
11/3/2023
07:00 am
edit
16.4%
BEAT
8/2/2023
07:00 am
edit
6.2%
BEAT
6/18
01:12 pm
Reiterates
Market Perform
Market Perform
Oppenheimer Holdings Inc.
Low
-0.2%
6/18
12:45 pm
Maintains
Perform
Perform
Oppenheimer
Low
0.8%
6/18
12:45 pm
Maintains
Perform
Perform
Oppenheimer
Low
0.8%
5/30
11:13 am
Maintains
In-Line
In-Line
Evercore ISI Group
Low
2.3%
5/9
02:03 pm
Maintains
Buy
Buy
Citigroup
Low
1.6%
6/27
05:03 pm
edit
Low
Form 8-K Editas Medicine, Inc. For: Jun 27
6/14
06:05 am
edit
Medium
Form 8-K Editas Medicine, Inc. For: Jun 14
6/6
04:17 pm
edit
Low
Form 4 Editas Medicine, Inc. For: Jun 04 Filed by: O'Neill Gilmore Neil
6/6
04:16 pm
edit
Low
Form 4 Editas Medicine, Inc. For: Jun 04 Filed by: Mei Baisong
6/3
05:15 pm
edit
Medium
Form 4 Editas Medicine, Inc. For: May 30 Filed by: Scadden David
Show more
Top News Gainers
6/7 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.2%
11/12 Q3/2019 9/30/2019 EPS -0.660 ZacksConsensus -0.730 ActVsEst 0.070 - Beat 6.9%
3/5 Editas Medicine Inc (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock. 5.2%
3/4 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 5.1%
8/29 Editas Medicine to Participate in Upcoming Investor Conferences 4.5%
6/14 Form 4 Editas Medicine, Inc. For: Jun 12 Filed by: Hirsch Andrew 4.0%
10/19 Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth [Yahoo! Finance News] 3.7%
11/13 Editas Expands Its Celgene Partnership After Another Strong Quarter [The Motley Fool] 3.7%
11/28 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 3.6%
5/4 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.4%
Top News Decliners
5/10 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.9%
4/1 Better Buy: Editas Medicine vs Sangamo Therapeutics [The Motley Fool] -8.1%
2/26 Form S-8 Editas Medicine, Inc. -6.8%
2/21 Editas Medicine Inc (NASDAQ: EDIT) is now covered by analysts at Wells Fargo & Co. They set an "equal weight" rating and a $28.00 price target on the stock. -6.7%
2/22 Better Buy: Editas Medicine vs. Intellia [The Motley Fool] -6.2%
7/30 Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update -5.8%
8/27 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.1%
4/30 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update -4.9%
11/26 Better Buy: Editas Medicine or Sangamo Therapeutics? [The Motley Fool] -4.6%
3/20 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.6%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3